Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Piroxicam (CP 16171), a new nonsteroidal anti-inflammatory agent, decreased pain, stiffness, and inflammation and increased the patient's ability to perform tasks in a double-blind study of patients with active, definite rheumatoid arthritis, poorly controlled despite standard therapy. Clinically and statistically significant improvement occurred in grip strength, walking time, and morning stiffness, and in patient and physician evaluation. Seventy-five per cent of the piroxicam-treated patients increased their daily activities. Three patients treated with the tablet form of piroxicam developed gastrointestinal ulcerations. Another patient developed iron deficiency anemia.
 ...
PMID:Piroxicam (CP 16171) in rheumatoid arthritis: a controlled clinical trial with novel assessment techniques. 34 91

Twenty-nine patients with acute gout were treated with piroxicam (40 mg daily for 5 days) in a multicentre general practitioner study. Pain relief was noticeable within 4 hours of the first dose and thereafter proceeded steadily, together with the early relief of other symptoms associated with acute gout. The prompt relief of symptoms was accompanied by a fall in serum uric acid. Piroxicam was well tolerated, eight experiencing side-effects that were mainly mild and gastro-intestinal in nature. The drug seems to be highly effective and safe in the treatment of acute gout.
 ...
PMID:Piroxicam in the treatment of acute gout: a multicentre open study in general practice. 52 Jun 53

Piroxicam is a nonsteroidal anti-inflammatory drug with a potent analgesic effect. In order to establish whether the analgesic action of Piroxicam has a central component, we studied the effect of the drug on the nociceptive orbicularis oculi reflexes evoked by electrical stimulation of the cornea and supraorbital nerve in healthy subjects. Piroxicam significantly suppressed the corneal reflex and R3 component of the blink reflex by 28% (p < 0.05) and 50% (p < 0.01), respectively. This effect was not reversed by the i.v. injection of naloxone. Beta-endorphin levels did not change. Piroxicam administration induces distinct inhibitory changes in nociceptive reflexes, which suggests that the analgesic action of the drug has a central component. The ineffectiveness of naloxone, and the lack of beta-endorphin changes, indicate that this central action is independent of the opioid system; other pain regulatory systems are probably involved.
 ...
PMID:Piroxicam-induced analgesia: evidence for a central component which is not opioid mediated. 147 79

Six orthopaedic clinics in Sweden made a comparison of the effects and side effects of Piroxicam (20 mg) and Indomethacin (100 mg) suppositories in 261 patients with painful coxarthrosis on the waiting list for total hip replacement (THR). The study was designed as a single blind study over 4 weeks. Amount of pain and range of motion was registered before the trial and compared with findings after 4 weeks, including reported side effects. Both drugs gave satisfactory pain relief without any appreciable variation on weightbearing or at rest. On the other hand, the trial showed a significant difference (p = 0.0033, Student's-test) between the two drugs as regards the frequency of side effects from the lower gastrointestinal tract, where piroxicam had a lower rate compared with indomethacin. No serious complications occurred; 16 patients dropped out, 8 in each group.
 ...
PMID:Piroxicam and indomethacin suppositories for painful coxarthrosis. 158 14

Piroxicam 0.5% gel, administered as 5 mg q.i.d. was compared to placebo gel in a double-blind study of the treatment of selected acute soft tissue injuries (ankle or acromioclavicular sprains, supraspinatus, or achilles tendinitis). A total of 200 patients (100 per treatment) were evaluated. Six patients (6%) in the piroxicam group discontinued treatment due to inefficacy, compared to 42/100 in the placebo group (p less than 0.001). Significantly greater reduction in pain (spontaneous and on movement), degree of joint restriction, pressure threshold and tenderness of the affected site were observed with piroxicam gel compared to placebo gel. The time to improvement was significantly less with the piroxicam gel. The overall evaluation of efficacy and of benefit to injury favoured piroxicam over placebo (p less than 0.0001). Both piroxicam and placebo gels were well tolerated, with 7 piroxicam and 15 placebo patients reporting primarily skin-related adverse effects. This study indicates that piroxicam 0.5% gel, administered as 5 mg q.i.d. is an effective treatment of musculoskeletal injuries (sprains and tendinitis), is significantly more effective than placebo, and is well tolerated.
 ...
PMID:Piroxicam 0.5% topical gel compared to placebo in the treatment of acute soft tissue injuries: a double-blind study comparing efficacy and safety. 204 Jan 4

An open comparative study on 75 patients with the aim to compare efficacy and safety of two non steroidal antiinflammatory drugs for topic use, piroxicam 1% cream (38 patients) and diclofenac 1% emulgel (37 patients) in the acute musculoskeletal disorders (tendinitis, distortion, muscular disorders etc.) has been carried out. Piroxicam has been administered at the dose of 0.5-1 g cream and diclofenac at the dose of 4 g emulgel, both 4 times a day for a period of 14 days. At baseline, 3rd, 7th and 14th days were evaluated: pain on movement, on pressure, function restriction, and the global evolution of symptomatology; at the end of the treatment the patient gave an evaluation on the physical characteristics of the two drugs, and the physician and the patients gave also global evaluation of efficacy and safety. The statistical analysis of the quantitative data (ANOVA and Student's t-tests) and qualitative data (Wilcoxon's test, chi 2 - and Fisher-tests) showed a significative reduction of pain on movement and of function's capacity at 3rd day, of pain on pressure and of function restriction on 7th day with both drugs with a superiority of piroxicam for some of the above mentioned parameters (7th and 14th days). Also the evaluation of the physical characteristics and the global evaluation of efficacy were more favourable for piroxicam. No adverse systemic or local reactions are reported for both drugs.
 ...
PMID:[Topical therapy of acute skeletal muscle diseases. Results of a comparative study on piroxicam cream 1% versus diclofenac emulgel 1%]. 214 33

36 patients with 432 menstrual cycles and primary dysmenorrhea were treated with Piroxicam-Jenapharm. Piroxicam-Jenapharm was given in a dose of 40 mg once daily for the first 2 days followed by 20 mg once daily. Piroxicam, a nonsteroidal-anti-inflammatory drug (NSAID) is an effective drug in reducing menstrual pain intensity in 80%. Piroxicam was well tolerated with no patient reporting side-effects. The treatment of primary dysmenorrhea with total 100 mg Piroxicam-Jenapharm over 3 days is recommended.
 ...
PMID:[Treatment of primary dysmenorrhea with Jenapharm piroxicam]. 223 87

A double-blind, parallel trial of 40 patients with chronic shoulder pain was carried out to compare alleviation of pain and improvement in mobility after treatment with 20 mg piroxicam each morning or 250 mg naproxen twice daily. During the 3-week study, patients also underwent conservative treatment of therapeutic exercise. Piroxicam was better than naproxen at relieving pain at night, but time, rather than a drug effect, seemed responsible for the improvement in shoulder abduction. No difference between the drugs was demonstrated regarding their effect on pain on active movement of the shoulder and external rotation.
 ...
PMID:Piroxicam versus naproxen in the treatment of painful shoulder. 242 35

In this study 198 patients with primary dysmenorrhea were entered into a double-blind, randomized crossover trial to study the efficiency of piroxicam compared to naproxen on menstrual pain and associated symptoms. The dosage for piroxicam was 40 mg on the first and second day of the menstrual cycle, and if necessary an additional 20 mg on the third day. The dosage for naproxen was 1,000 mg on the first and second day, and if necessary an additional 500 mg on the third day. Piroxicam and naproxen afforded high relief from menstrual pain and associated symptoms. The drugs were well tolerated with only a few side effects of a mild nature. There were no statistically significant differences between piroxicam and naproxen.
 ...
PMID:[Piroxicam versus naproxen in primary dysmenorrhea]. 264 53

An open, parallel trial was conducted to compare the efficacy and toleration of piroxicam 0.5% gel and diclofenac 1.16% topical gel preparations in the treatment of 173 patients with well-defined, acute sprains and tendinitis of the ankle, shoulder, or elbow. Therapy was begun within three to five days of the injury and continued for up to 14 days. Piroxicam gel was applied to the injured area four times daily by 84 patients and diclofenac gel was similarly applied by 89 patients. Pain, tenderness, and restriction of joint movement were markedly improved with both drugs after three days of treatment. Further improvement was noted after 14 days of treatment and patients generally resumed normal activities in nine days. There was no difference in the response to treatment or in the global impressions of efficacy between piroxicam and diclofenac. Toleration was regarded as good or excellent by 98% of patients receiving piroxicam and 94% of patients receiving diclofenac. There were few adverse effects reported by either group. The type and incidence of these effects were similar for both drugs, with the majority consisting of mild or moderate local skin reactions at the site of application. The results of this study show that piroxicam 0.5% gel and diclofenac 1.16% gel are equally effective and well tolerated in the treatment of selected acute sprains and tendinitis.
 ...
PMID:A clinical evaluation of piroxicam gel: an open comparative trial with diclofenac gel in the treatment of acute musculoskeletal disorders. 266 65


1 2 3 4 5 6 Next >>